FDA Webview

Free FDA Notices

Drug Products Not Withdrawn for S&E


Federal Register Notice: FDA has determined that 12 drug products listed in this document were not withdrawn from sale for reasons of safety or effectiveness. This determination will allow FDA to continue to approve ANDAs that refer to the products as long as they meet relevant legal and regulatory requirements. These products include GlaxoSmithKline’s Thorazine HCl tablets, Teva Pharmaceutical’s Cytarabine Injectable, and Par Pharmaceutical’s Capoten tablets. To view this notice, click here.